Shopping Cart
Remove All
Your shopping cart is currently empty
BI8626 is a ubiquitin ligase HUWE1 inhibitor with protective effects against spontaneous desiccation syndrome in NOD/ShiLtj mice.BI8626 inhibits intracellular cholesterol and decreases the expression of phosphorylated ZAP-70, CD25, and other activation markers, and inhibits the proliferation of CD4 T-cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $84 | - | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $289 | In Stock | In Stock | |
| 25 mg | $513 | - | In Stock | |
| 50 mg | $728 | - | In Stock | |
| 100 mg | $985 | - | In Stock | |
| 200 mg | $1,330 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $226 | - | In Stock |
| Description | BI8626 is a ubiquitin ligase HUWE1 inhibitor with protective effects against spontaneous desiccation syndrome in NOD/ShiLtj mice.BI8626 inhibits intracellular cholesterol and decreases the expression of phosphorylated ZAP-70, CD25, and other activation markers, and inhibits the proliferation of CD4 T-cells. |
| Targets&IC50 | HUWE1:0.9 μM |
| In vitro | In LS174T cells, BI8626 (0μM, 5μM, 10μM, 15μM, 20μM; 0-4 days) delayed progression through all phases of the cell cycle, with the most pronounced effect on the G1 phase[1]. |
| Molecular Weight | 440.54 |
| Formula | C25H28N8 |
| Cas No. | 1875036-75-1 |
| Smiles | NCc1cccc(CNc2ncnc3c(ncnc23)N2CCN(Cc3ccccc3)CC2)c1 |
| Relative Density. | 1.302 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Viscous |
| Storage | store at low temperature,keep away from direct sunlight | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (136.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.54 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.